High Spatial Resolution Dosimetry For Radioactive Plaques Used For Radiotherapy Of Eye Lesions
Funder
National Health and Medical Research Council
Funding Amount
$357,294.00
Summary
Melanoma and squamous cell carcinoma are the commonest ocular malignancies in adults. While plaque brachytherapy has delivered advances in ocular cancer management, significant challenges remain. These include post-treatment vision loss (due to over irradiation of vital structures, e.g. optic nerve), treatment failure (~10%) and an inability to treat large tumours (>8mm thick). This project aims to address these challenges through rigorous quality assurance and enhanced dosimetry planning.
Development Of A Novel Bioengineered Tissue Construct For Repairing The Eye.
Funder
National Health and Medical Research Council
Funding Amount
$335,817.00
Summary
Corneal diseases are often treated using donor tissue transplants. Nevertheless, donor tissue is unsuitable for treating the peripheral or limbal margin of the cornea. We have therefore developed a way to transplant sheets of limbal tissue (epithelium) grown in the laboratory from a patient's own cells, but this tissue lacks a foundation of connective tissue that we believe is essential for sustained healing. Thus, our aim is to develop a novel limbal transplant which contains both layers.
The Impact Of Pseudomonas Aeruginosa Biofilm On Eye Infection And The Development Of Antimicrobial Contact Lenses
Funder
National Health and Medical Research Council
Funding Amount
$328,932.00
Summary
Worldwide, 125 million people correct their vision through the use of contact lenses. Contact lens use predisposes the wearer to sight threatening eye infections. Despite advanced material technology and improved hygiene regimens, the rate of contact lens-related infectious disease has remained constant. This research aims to elucidate how bacteria compromise the ocular immune system in order to develop preventative/therapeutic strategies to combat ocular infections.
Gene Transfer For Corneal Transplantation And Limbal Stem Cell Transplantation
Funder
National Health and Medical Research Council
Funding Amount
$743,463.00
Summary
The cornea is the clear window at the front of the eye. Corneal disease is the second most common reason for blindness in the world. It is sometimes made worse by additional disease affecting the ocular surface. Replacement of a damaged cornea, or of the elements that maintain a normal ocular surface, is possible by transplantation of tissue (either the cornea or the limbus) from a donor eye. The alternative, an artificial cornea, has never yet been reported to function nearly as well as does a ....The cornea is the clear window at the front of the eye. Corneal disease is the second most common reason for blindness in the world. It is sometimes made worse by additional disease affecting the ocular surface. Replacement of a damaged cornea, or of the elements that maintain a normal ocular surface, is possible by transplantation of tissue (either the cornea or the limbus) from a donor eye. The alternative, an artificial cornea, has never yet been reported to function nearly as well as does a successful corneal graft, because the interface between the patient and the prosthesis breaks down and serious problems such as infection are common. Transplantation of the cornea is very successful in some patients but in a sizable subgroup, the graft will fail because of an unwanted immune response. Rejection is the usual cause of a graft failure. Grafts to repair a damaged ocular surface also fail from rejection. Overcoming an unwanted immune response would improve the outcome of corneal transplantation by as much as thirty percent. Overcoming the twin problems of corneal graft rejection and ocular surface disease would make transplantation a feasible option for millions of blind individuals. Novel approaches to abrogation of the immune response to ocular tissue grafts are required, because the many developments in immunosuppression that have improved the survival of other types of transplants have not improved the outcome for grafts in the eye. The immunobiology of the eye is sufficiently different from that of solid organs to demand a different approach. We plan to investigate the use of localised gene transfer to donor eye tissue prior to transplantation, to improve corneal graft and limbal graft outcome.Read moreRead less
The Role Of Collagenase (MMP-1) In The Pathogenesis Of Human Pterygia
Funder
National Health and Medical Research Council
Funding Amount
$246,100.00
Summary
Pterygia are a common, recurrent, disfiguring, and sight-threatening disease of the human eye. This disease is extremely common world wide and particularly in the Australian aboriginal population. The triggers for this disease are unknown. Prolonged exposure to environmental elements, such as ultra violet (UV) light, is proposed to be the main initiating factor. Our previous studies have shown the important role played by a family of proteolytic enzymes (metalloproteinases) in the progressive an ....Pterygia are a common, recurrent, disfiguring, and sight-threatening disease of the human eye. This disease is extremely common world wide and particularly in the Australian aboriginal population. The triggers for this disease are unknown. Prolonged exposure to environmental elements, such as ultra violet (UV) light, is proposed to be the main initiating factor. Our previous studies have shown the important role played by a family of proteolytic enzymes (metalloproteinases) in the progressive and invasive nature of pterygia. We have significant preliminary evidence that a large percentage of patients with pterygia carry a mutation in one of these enzymes (collagenase-1). This is the most abundant enzyme expressed in pterygium tissue and probably plays a major role in invasion and progression in this disease. UV light activates cells in pterygia to induce expression of collagenase-1. This study will determine whether or not people with a genetic predisposition are more likely to develop pterygia and whether or not environmental factors, such as UV light, trigger progression of disease. If this is the case, then subjects with this genetic predisposition would be at increased risk for the development of pterygia (and their complications) and could be advised to take preventative measures to minimize the risk of developing this disease.Read moreRead less
Early Detection Of Alzheimer's Disease Using Ocular Biomarkers
Funder
National Health and Medical Research Council
Funding Amount
$602,502.00
Summary
Curcumin fluorescence imaging of the retina will be tested for quantification of retinal amyloid plaque burden and rate of change. This will be compared to AD disease status, brain plaque burden and other markers to evaluate retinal imaging as an early test for AD.
Therapeutics For Repair And Regeneration Of The Cornea
Funder
National Health and Medical Research Council
Funding Amount
$166,087.00
Summary
Corneal disease is the commonest cause of irreversible blindness and of the 50 million people world-wide who are bilaterally blind, 10 million are blind from corneal involvement. This proposal will address corneal disease by 1. innovative translational research for corneal repair and regeneration; 2. developing evidence-based management guidelines for corneal disease, and 3. by optimising health service delivery.
Functional Analysis Of Recently Identified Novel Glaucoma Genes.
Funder
National Health and Medical Research Council
Funding Amount
$519,918.00
Summary
Glaucoma is the commonest cause of irreversible blindness in the world. Recently, through genetic studies in cohorts of blinding glaucoma cases from Australia, our group has found that variants in two genes increase the risk of blinding glaucoma. This project will investigate how these genes contribute to pathological changes in the optic nerve and retina, at the back of the eye, that lead to glaucoma. This knowledge will be useful for developing new strategies to treat glaucoma.
Minimally-invasive Gene Delivery Of A Novel Inhibitor Of Retinal Angiogenesis
Funder
National Health and Medical Research Council
Funding Amount
$883,883.00
Summary
Excessive growth of blood vessels in the eye causes vision loss and can only be treated with lasers or painful and frequent injections into the eye. Vasostatin is a specific inhibitor of angiogenesis and a promising agent for the management of ocular neovascularisation. We will provide pre-clinical evidence that gene delivery of vasostatin-like peptides is an effective therapeutic strategy and it has potential to revolutionize the current ophthalmic care of age-related macular degeneration.